DNA has 36-month beta value of 1.17. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DNA is 1.40B, and currently, short sellers hold a 17.50% ratio of that float. The average trading volume of DNA on June 21, 2024 was 42.39M shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
DNA) stock’s latest price update
The stock of Ginkgo Bioworks Holdings Inc (NYSE: DNA) has increased by 0.26 when compared to last closing price of 0.41. Despite this, the company has experienced a -11.31% fall in its stock price over the last five trading sessions. investorplace.com reported 2024-06-20 that Investing in penny stocks can reward bold, patient investors. But patience can be in short supply when you can just buy NVIDIA (NASDAQ: NVDA ) and sleep well at night.
DNA’s Market Performance
Ginkgo Bioworks Holdings Inc (DNA) has seen a -11.31% fall in stock performance for the week, with a -43.97% decline in the past month and a -64.06% plunge in the past quarter. The volatility ratio for the week is 8.74%, and the volatility levels for the past 30 days are at 8.56% for DNA. The simple moving average for the past 20 days is -23.07% for DNA’s stock, with a -68.10% simple moving average for the past 200 days.
Analysts’ Opinion of DNA
Raymond James gave a rating of “Mkt Perform” to DNA, setting the target price at $2.50 in the report published on November 14th of the previous year.
DNA Trading at -45.04% from the 50-Day Moving Average
After a stumble in the market that brought DNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -83.90% of loss for the given period.
Volatility was left at 8.56%, however, over the last 30 days, the volatility rate increased by 8.74%, as shares sank -41.50% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -63.38% lower at present.
During the last 5 trading sessions, DNA fell by -11.23%, which changed the moving average for the period of 200-days by -81.77% in comparison to the 20-day moving average, which settled at $0.5181. In addition, Ginkgo Bioworks Holdings Inc saw -75.75% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at DNA starting from Dmytruk Mark E., who sale 48,866 shares at the price of $0.55 back on Jun 03 ’24. After this action, Dmytruk Mark E. now owns 984,662 shares of Ginkgo Bioworks Holdings Inc, valued at $26,827 using the latest closing price.
Coen Steven P. sale 13,440 shares at $0.55 during a trade that took place back on Jun 03 ’24, which means that Coen Steven P. is holding 178,832 shares at $7,379 based on the most recent closing price.
Stock Fundamentals for DNA
Current profitability levels for the company are sitting at:
- -3.76 for the present operating margin
- 0.7 for the gross margin
The net margin for Ginkgo Bioworks Holdings Inc stands at -4.09. The total capital return value is set at -0.55. Equity return is now at value -65.81, with -42.70 for asset returns.
Based on Ginkgo Bioworks Holdings Inc (DNA), the company’s capital structure generated 0.19 points at debt to capital in total, while cash flow to debt ratio is standing at -1.21. The debt-to-equity ratio resting at 0.24. The interest coverage ratio of the stock is -8427.26.
Currently, EBITDA for the company is -600.68 million with net debt to EBITDA at 1.25. When we switch over and look at the enterprise to sales, we see a ratio of 1.43. The receivables turnover for the company is 8.5 for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.34.
Conclusion
To put it simply, Ginkgo Bioworks Holdings Inc (DNA) has had a bad performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
